Invasive mosquito located at Alameda County Fairgrounds in Pleasanton
According to the Alameda County Mosquito Abatement District, larvae was found in a trap at the fairgrounds in Pleasanton on July 30.
Several Aedes aegypti mosquitoes were found in the same area in October of last year. Before last year's discoveries, the mosquito was not seen in the county since 2014.
Dr. Eric Haas-Stapleton, the district's laboratory director, said Monday, "We responded the next day by increasing our mosquito monitoring, inspection, and treatment efforts at the Alameda County Fairgrounds and surrounding neighborhoods."
Also known as the yellow fever mosquito, officials said Aedes aegypti can spread multiple diseases, including dengue and Zika. The mosquito is described as aggressive and bites throughout the day.
Officials urged residents in Pleasanton and throughout the county to inspect their properties for standing water. The mosquitoes are container breeders, laying eggs in small water sources such as buckets, pet dishes, fountains, bird baths and old tires.
Aedes aegypti eggs are extremely small and are often mistaken for dirt or seeds. The mosquito can grow from an egg into an adult in as little as a bottle cap of water, officials said.
Adult Aedes aegypti mosquitoes are described as less than a quarter inch long, with black and white stripes on its back and legs. The district said the non-native mosquito has been found in at least 26 of California's 58 counties, including neighboring counties.
Residents are urged to protect themselves by using insect repellent, wearing long-sleeve shirts, pants, socks and shoes when mosquitoes are most active and to ensure window and door screens are in good condition.
Anyone who sees the mosquitoes are urged to contact the district through their website or by calling 510-783-7744.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
41 minutes ago
- Yahoo
Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results
- Conference Call and Webcast Today, August 7, 2025, at 4:30 p.m. ET PASADENA, Calif., August 07, 2025--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is hosting a conference call today, August 7, 2025, at 4:30 p.m. ET to discuss the results. "Arrowhead continues to achieve strong execution in discovery, clinical and regulatory, and business development. Our pipeline has become quite mature, with four Arrowhead discovered candidates currently in pivotal Phase 3 studies. In addition, our commercial buildout is designed to make us launch ready on day one, should plozasiran receive regulatory approval on the November 18, 2025, PDUFA date," said Christopher Anzalone, Ph.D., President and CEO at Arrowhead. "We continue to maintain a strong balance sheet, which we believe gives us the financial resources to move multiple innovative new medicines through the clinical and regulatory process and ultimately get them to the patients who need them." Selected Recent Events Announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead created to develop and commercialize four of Arrowhead's investigational cardiometabolic candidates in Greater China. Summary terms of the agreement include: Visirna will receive an upfront payment of $130 million from Sanofi. In addition, Visirna will be eligible to receive further milestone payments of up to $265 million upon approval of plozasiran across various indications in mainland China. Sanofi will receive an exclusive license to develop and commercialize investigational plozasiran in Greater China from Visirna Therapeutics, offering potential treatment to people living with elevated triglycerides. Earned a $100 million milestone payment from Sarepta Therapeutics when Arrowhead reached the first of two prespecified enrollment targets and subsequent authorization to dose escalate in a Phase 1/2 clinical study of ARO-DM1, an investigational RNA interference (RNAi) therapeutic for the treatment of type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystrophy. Arrowhead currently expects to achieve the second enrollment target by the end of 2025, which would trigger an additional $200 million milestone payment from Sarepta. Completed enrollment in investigational plozasiran clinical studies SHASTA-3, SHASTA-4, and MUIR-3, the company's global Phase 3 clinical studies designed to support regulatory submissions for marketing approval in the treatment of severe hypertriglyceridemia. Arrowhead anticipates completing the primary portion of these studies in mid-2026 with topline data expected shortly thereafter and planned submissions for regulatory review and potential approval to follow. The company previously submitted a New Drug Application (NDA) for plozasiran based on positive Phase 3 PALISADE study results in patients with familial chylomicronemia syndrome, which the U.S. FDA has accepted with a Prescription Drug User Fee Act (PDUFA) action date set for November 18, 2025. Dosed the first subject in the YOSEMITE Phase 3 clinical trial of zodasiran, the company's investigational RNAi therapeutic being developed as a potential treatment for homozygous familial hypercholesterolemia (HoFH), a rare genetic condition that leads to severely elevated LDL-cholesterol and early onset cardiovascular disease. Zodasiran is the fourth investigational RNAi-based candidate developed by Arrowhead to reach late-stage pivotal studies, after investigational drugs plozasiran, fazirsiran (licensed to Takeda) and olpasiran (licensed to Amgen). Dosed the first subjects in a Phase 1/2a clinical trial of ARO-ALK7, the company's investigational RNAi therapeutic being developed as a potential treatment for obesity. ARO-ALK7 is designed to intervene in a known pathway that signals the body to store fat in adipose tissue with a novel mechanism of action that may better preserve lean muscle mass compared to currently approved obesity therapies. The study initiates in otherwise healthy obese subjects using single and multiple escalating doses of ARO-ALK7 monotherapy and is expected to progress rapidly to investigate combinations of ARO-ALK7 with tirzepatide in obese patients with and without type 2 diabetes. Selected Fiscal 2025 Third Quarter Financial Results ARROWHEAD PHARMACEUTICALS, INC. CONSOLIDATED CONDENSED FINANCIAL INFORMATION (in thousands, except per share amounts) Three Months Ended June 30, OPERATING SUMMARY 2025 2024 (Unaudited) Revenue $ 27,767 $ — Operating Expenses: Research and development 162,368 152,431 General and administrative expenses 30,949 23,710 Total operating expenses 193,317 176,141 Operating loss (165,550 ) (176,141 ) Total other (expense) income (13,539 ) 2,164 Loss before income tax expense and noncontrolling interest (179,089 ) (173,977 ) Income tax (benefit) expense (437 ) — Net loss including noncontrolling interest (178,652 ) (173,977 ) Net loss attributable to noncontrolling interest, net of tax (3,411 ) (3,184 ) Net loss attributable to Arrowhead Pharmaceuticals, Inc. $ (175,241 ) $ (170,793 ) Net loss per share attributable to Arrowhead Pharmaceuticals, Inc. - Diluted $ (1.26 ) $ (1.38 ) Weighted-average shares used in calculating - Diluted 139,039 124,199 FINANCIAL POSITION SUMMARY June 30, 2025 September 30, 2024 (unaudited) Cash, cash equivalents and restricted cash $ 129,793 $ 102,685 Available-for-sale securities, at fair value 770,579 578,276 Total cash resources (Cash, cash equivalents and restricted cash and Available-for-sale securities, at fair value) 900,372 680,961 Other current and long-term assets 480,240 458,841 Total Assets $ 1,380,612 $ 1,139,802 Liability related to the sale of future royalties $ 360,254 $ 341,361 Credit Facility 240,332 393,183 Deferred revenue 22,979 — Other liabilities 237,241 214,195 Total Liabilities $ 860,806 $ 948,739 Total Arrowhead Pharmaceuticals, Inc. Stockholders' Equity 522,313 185,444 Noncontrolling Interest (2,507 ) 5,619 Total Noncontrolling Interest and Stockholders' Equity $ 519,806 $ 191,063 Total Liabilities, Noncontrolling Interest and Stockholders' Equity $ 1,380,612 $ 1,139,802 Shares Outstanding 138,144 124,376 Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at Once registered, you will receive the dial-in number and a personalized PIN code that will be required to access the call. About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing. For more information, please visit or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit Safe Harbor Statement under the Private Securities Litigation Reform Act: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "hope," "intend," "plan," "project," "could," "estimate," "continue," "target," "forecast" or "continue" or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, including the timing of achievement of the next ARO-DM1 milestone, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements, including our ability to achieve such milestones on projected timelines (if at all) and receive timely payment if milestones are achieved; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We disclaim any intention to update or revise forward-looking statements to reflect new events or circumstances. Source: Arrowhead Pharmaceuticals, Inc. View source version on Contacts Arrowhead Pharmaceuticals, Anzalone, CFA626-304-3400ir@ Investors: LifeSci Advisors, LLCBrian Ritchie212-915-2578britchie@ Media: LifeSci Communications, LLCKendy Guarinoni, Ph.D.724-910-9389kguarinoni@
Yahoo
an hour ago
- Yahoo
Chikungunya cases double in Singapore as outbreak sparks travel warnings; Universities join vape war with disposal bin campaign: Singapore live news
Singapore is facing a notable surge in chikungunya cases, with 17 reported by early August 2025, more than double the previous year's count. The rise began in May and accelerated through July, largely driven by travellers returning from outbreak zones like China and Indian Ocean islands. While local transmission remains low, the presence of Aedes mosquitoes poses an ongoing risk. Chikungunya, a virus spread by mosquito bites, causes fever, rash, and severe joint pain, and though rarely fatal, it can lead to lasting discomfort. China's outbreak has surpassed 8,000 cases, prompting global health alerts from the World Health Organisation (WHO). Singaporean authorities urge preventive measures such as repellents, protective clothing and mosquito control. More on the rising chikungunya cases here. Singapore's universities are fighting back against youth vaping with new disposal bins and stricter campus rules. The 'Bin the Vape' campaign offers students a safe, discreet and penalty-free way to quit, while institutions ramp up surveillance and education. While disciplinary actions remain for those caught vaping, voluntary disposal and help-seeking are encouraged. Institutions like NUS and NTU have introduced stricter rules, including suspensions and housing bans, alongside enhanced surveillance and education. With 2,000 cases reported in 2024, the crackdown is timely and necessary. Read more in our live blog below, including the latest local and international news and updates. Singapore monitors chikungunya surge after 17 cases reported in August Singapore is seeing an increase in chikungunya cases, with 17 reported by 2 August, more than double the count from the same period last year. Health authorities recorded a steady increase in cases that saw nine infections May, 13 in June and 16 in July. Most infections are linked to travellers returning from outbreak zones, including China and Indian Ocean islands like La Réunion and Mayotte. Local transmission remains limited, but the presence of Aedes mosquitoes keeps health officials on high alert. Chikungunya is a mosquito-borne virus that causes fever, rash and debilitating joint pain. Though rarely fatal, it can lead to long-term disability. Symptoms are managed with rest and fluids. The World Health Organisation (WHO) has issued a global warning, urging countries to ramp up mosquito control and public awareness. China, facing its largest outbreak since 2008, has reported over 8,000 cases, mostly in Foshan. The Communicable Diseases Agency (CDA) advises travellers to use insect repellent, wear protective clothing and seek medical attention if symptoms arise. Preventing mosquito breeding at home is also key. Read on the rising chikungunya cases here. Vape bins rolled out across Singapore universities Singapore's six autonomous universities have installed vape disposal bins as part of the 'Bin the Vape' campaign, a joint initiative by the Health Sciences Authority (HSA) and People's Association (PA). With youth vaping cases doubling to 2,000 in 2024, the move aims to offer a discreet, penalty-free way for students to surrender e-vaporisers. Each university has placed at least one bin on campus, with plans to expand based on demand. The campaign also extends to 23 community clubs islandwide. Students caught vaping still face disciplinary action, but those who voluntarily dispose of devices or seek help are spared penalties. Institutions like NUS and NTU have tightened rules, including suspensions and housing bans for offenders. Orientation sessions now include anti-vape education, and some campuses use CCTV and whistleblowing channels to monitor activity. The Ministry of Health (MOH) is also classifying etomidate, a sedative found in some vapes, as a Class C controlled drug. An amnesty period allows users to surrender devices before the law kicks in. With vaping increasingly linked to synthetic drug abuse and aggressive behaviour, Singapore's universities are stepping up enforcement and support, joining the broader vape war against smugglers at land checkpoints and peddlers near schools. Singapore is seeing an increase in chikungunya cases, with 17 reported by 2 August, more than double the count from the same period last year. Health authorities recorded a steady increase in cases that saw nine infections May, 13 in June and 16 in July. Most infections are linked to travellers returning from outbreak zones, including China and Indian Ocean islands like La Réunion and Mayotte. Local transmission remains limited, but the presence of Aedes mosquitoes keeps health officials on high alert. Chikungunya is a mosquito-borne virus that causes fever, rash and debilitating joint pain. Though rarely fatal, it can lead to long-term disability. Symptoms are managed with rest and fluids. The World Health Organisation (WHO) has issued a global warning, urging countries to ramp up mosquito control and public awareness. China, facing its largest outbreak since 2008, has reported over 8,000 cases, mostly in Foshan. The Communicable Diseases Agency (CDA) advises travellers to use insect repellent, wear protective clothing and seek medical attention if symptoms arise. Preventing mosquito breeding at home is also key. Read on the rising chikungunya cases here. Singapore's six autonomous universities have installed vape disposal bins as part of the 'Bin the Vape' campaign, a joint initiative by the Health Sciences Authority (HSA) and People's Association (PA). With youth vaping cases doubling to 2,000 in 2024, the move aims to offer a discreet, penalty-free way for students to surrender e-vaporisers. Each university has placed at least one bin on campus, with plans to expand based on demand. The campaign also extends to 23 community clubs islandwide. Students caught vaping still face disciplinary action, but those who voluntarily dispose of devices or seek help are spared penalties. Institutions like NUS and NTU have tightened rules, including suspensions and housing bans for offenders. Orientation sessions now include anti-vape education, and some campuses use CCTV and whistleblowing channels to monitor activity. The Ministry of Health (MOH) is also classifying etomidate, a sedative found in some vapes, as a Class C controlled drug. An amnesty period allows users to surrender devices before the law kicks in. With vaping increasingly linked to synthetic drug abuse and aggressive behaviour, Singapore's universities are stepping up enforcement and support, joining the broader vape war against smugglers at land checkpoints and peddlers near schools.
Yahoo
an hour ago
- Yahoo
WHO says nearly 100,000 struck with cholera in Sudan
The World Health Organization on Thursday said nearly 100,000 cholera cases had been reported in Sudan since July last year, as it warned of more hunger, displacement and disease to come. Since April 2023, Sudan has been torn apart by a power struggle between army chief Abdel Fattah al-Burhan and Mohamed Hamdan Daglo, commander of the rival paramilitary Rapid Support Forces. The fighting has killed tens of thousands. "In Sudan, unrelenting violence has led to widespread hunger, disease and suffering," said WHO chief Tedros Adhanom Ghebreyesus. "Cholera has swept across Sudan, with all states reporting outbreaks. Nearly 100,000 cases have been reported since July last year." Oral cholera vaccination campaigns had been conducted in several states, including the capital Khartoum, he told a press conference with the Geneva UN correspondents' association ACANU. "While we are seeing a declining trend in numbers, there are gaps in disease surveillance, and progress is fragile," he said. "Recent floods, affecting large parts of the country, are expected to worsen hunger and fuel more outbreaks of cholera, malaria, dengue and other diseases." Cholera is an acute intestinal infection that spreads through food and water contaminated with bacteria, often from faeces. It causes severe diarrhoea, vomiting and muscle cramps. Cholera can kill within hours when not attended to, though it can be treated with simple oral rehydration, and antibiotics for more severe cases. There has been a global increase in cholera cases, and their geographical spread, since 2021. - Malnutrition - As for hunger, Tedros said there were reports from El-Fasher, the besieged capital of North Darfur state, that people were eating animal feed to survive. Across the country, millions are going hungry and around 770,000 children under five years old are expected to suffer from severe acute malnutrition this year. "In the first six months of this year, nutrition centres supported by WHO have treated more than 17,000 severely malnourished children with medical complications. But many more are beyond reach," Tedros warned. The UN health agency's efforts were being held back by limited access and a lack of funding, he added, with the WHO having received less than a third of the money it has appealed for to provide urgent health assistance in Sudan. The WHO director-general said that as long as the violence continues in Sudan, "we can expect to see more hunger, more displacement and more disease". rjm/rlp
